CoChat
Sign Up
Cited by 2,747Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismHealth Promotion and Cardiovascular Prevention

The DOI matches its Crossref record, with a small difference in title or year.

The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease

·1984·JAMA
DOI 10.1001/jama.1984.03340270029025
Open this paper in CoChat — free account

Abstract

The Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT), a multicenter, randomized, double-blind study, tested the efficacy of cholesterol lowering in reducing risk of coronary heart disease (CHD) in 3,806 asymptomatic middle-aged men with primary hypercholesterolemia (type II hyperlipoproteinemia). The treatment group received the bile acid sequestrant cholestyramine resin and the control group received a placebo for an average of 7.4 years. Both groups followed a moderate cholesterol-lowering diet. The cholestyramine group experienced average plasma total and low-density lipoprotein cholesterol (LDL-C) reductions of 13.4% and 20.3%, respectively, which were 8.5% and 12.6% greater reductions than those obtained in the placebo group. The cholestyramine group experienced a 19% reduction in risk (p less than .05) of the primary end point--definite CHD death and/or definite nonfatal myocardial infarction--reflecting a 24% reduction in definite CHD death and a 19% reduction in nonfatal myocardial infarction. The cumulative seven-year incidence of the primary end point was 7% in the cholestyramine group v 8.6% in the placebo group. In addition, the incidence rates for new positive exercise tests, angina, and coronary bypass surgery were reduced by 25%, 20%, and 21%, respectively, in the cholestyramine group. The risk of death from all causes was only slightly and not significantly reduced in the cholestyramine group. The magnitude of this decrease (7%) was less than for CHD end points because of a greater number of violent and accidental deaths in the cholestyramine group. The LRC-CPPT findings show that reducing total cholesterol by lowering LDL-C levels can diminish the incidence of CHD morbidity and mortality in men at high risk for CHD because of raised LDL-C levels. This clinical trial provides strong evidence for a causal role for these lipids in the pathogenesis of CHD.

Overview

Integrity signals

Registry

Crossref · 10.1001/jama.1984.03340270029025

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cited by

Sorted by citations

Items 701–800 of 1,025

Related

See all

Metadata

Venue
JAMA
Publisher
American Medical Association (AMA)
Published
1984-01-20
Volume
251
Issue
3
Pages
351
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
DOI
10.1001/jama.1984.03340270029025
OpenAlex
W4248021162
Cited by
2,747
References
0
Citations by year
2026: 18 · 2025: 14 · 2024: 27 · 2023: 19 · 2022: 20 · 2021: 26 · 2020: 17 · 2019: 34 · 2018: 31 · 2017: 33 · 2016: 42 · 2015: 58 · 2014: 51 · 2013: 46 · 2012: 45
FWCI
196.69
Type
journal article
Language
en
Open access
closed
Locations
  • JAMA (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
Keywords
cholestyramine, bile acid sequestrants, primary hypercholesterolemia, type II hyperlipoproteinemia, coronary artery disease, LDL cholesterol, total cholesterol, myocardial infarction, coronary heart disease mortality, cholesterol-lowering diet, cardiovascular risk reduction
MeSH terms
Adult, Cholesterol, Cholestyramine Resin, Clinical Trials as Topic, Coronary Disease, Double-Blind Method, Humans, Hypercholesterolemia, Lipoproteins, Male, Middle Aged, Mortality

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review